There are 2867 resources available
1198TiP - A phase Ib/II open-label, nonrandomized study of FGFR inhibitor futibatinib in combination with MEK inhibitor binimetinib in patients with advanced KRAS-mutant cancer
Presenter: Jordi Rodon
Session: Poster session 16
1199TiP - Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC
Presenter: Aaron Lisberg
Session: Poster session 16
1200TiP - Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)
Presenter: Hakan Sedat Orer
Session: Poster session 16
1206P - HER2 copy number variation (CNV), HER2 expression and primary resistance mechanisms in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction cancer (mGC/GEJC) receiving first-line chemotherapy (CT) + trastuzumab (T) +/- pertuzumab (P) in the JACOB trial
Presenter: Filippo Pietrantonio
Session: Poster session 16
1209P - A phase II study of regorafenib in combination with nivolumab in patients with recurrent or metastatic solid tumors: Results of the ESCC cohort
Presenter: Li-Yuan Bai
Session: Poster session 16
1211P - A multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (EPOC1802)
Presenter: Hideaki Bando
Session: Poster session 16